# Application of SERS Technology in Clinical Diagnosis and Prognosis of Lung Cancer Immunotherapy

> **NCT05885815** · — · UNKNOWN · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 500 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05885815
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06
- **Primary completion:** 2024-06
- **Final completion:** 2025-06
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05885815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05885815, "Application of SERS Technology in Clinical Diagnosis and Prognosis of Lung Cancer Immunotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05885815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*